Get the Stockscreener App
0.8286
4.89%
0.0386
Pre-market:
.91
0.0814
+9.82%
Windtree Therapeutics Inc stock is traded at $0.8286, with a volume of 13.17M.
It is up +4.89% in the last 24 hours and up +39.97% over the past month.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
See More
Previous Close:
$0.79
Open:
$0.8676
24h Volume:
13.17M
Relative Volume:
2.08
Market Cap:
$3.03M
Revenue:
-
Net Income/Loss:
$-11.38M
P/E Ratio:
-0.0299
EPS:
-27.73
Net Cash Flow:
$-12.72M
1W Performance:
+5.49%
1M Performance:
+39.97%
6M Performance:
+240.99%
1Y Performance:
-77.61%
1-Day Range:
$0.74
$0.8689
1-Week Range:
$0.63
$1.04
52-Week Range:
$0.0915
$14.75
Windtree Therapeutics Inc Stock (WINT) Company Profile
Name
Windtree Therapeutics Inc
Sector
Industry
Phone
(215) 488-9300
Address
2600 KELLY ROAD, WARRINGTON, PA
Compare WINT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WINT
Windtree Therapeutics Inc
|
0.8286 | 2.88M | 0 | -11.38M | -12.72M | -27.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.20 | 119.76B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.96 | 59.14B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.12 | 41.40B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
555.96 | 32.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.70 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Windtree Therapeutics Inc Stock (WINT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-20 | Initiated | Ladenburg Thalmann | Buy |
Windtree Therapeutics Inc Stock (WINT) Latest News
Why Windtree Therapeutics Inc. stock attracts strong analyst attentionSteady Profit Stock Forecasts - Newser
What makes Windtree Therapeutics Inc. stock price move sharply200 Percent Profit Outlook - Newser
Windtree Therapeutics (WINT) Soars 13.92% on U.S. Patent Issuance - AInvest
Windtree Therapeutics Explodes 27%—What’s Fueling the Surge? - AInvest
Why WINT Stock is Surging? - StocksToTrade
Windtree Therapeutics Soars 76.71% on Patent Win - AInvest
Windtree Therapeutics Receives $7 Million Offer for Preclinical Oncology Platform - MSN
Windtree Therapeutics (NASDAQ:WINT) Trading Down 14.1% – Here’s What Happened - Defense World
Windtree Therapeutics Secures U.S. Patent for Istaroxime Heart Failure Treatment - MSN
Windtree Therapeutics Plunges 12.06% Amid High Short Interest - AInvest
Windtree Therapeutics Soars 25.97% on Patent Win - AInvest
Windtree Therapeutics Advances Istaroxime Phase 2 Study with Interim Analysis Enrollment - MSN
Windtree’s Stock Upsurge: Is Innovation the Key? - StocksToTrade
Windtree Therapeutics raises $253,333 through convertible notes and warrants - Investing.com
Windtree Therapeutics receives U.S. patent for istaroxime heart failure drug - Investing.com
Windtree Therapeutics Announces U.S. Patent Grant for Istaroxime in Acute Heart Failure Treatment - Nasdaq
Windtree Therapeutics receives U.S. patent for istaroxime heart failure drug By Investing.com - Investing.com India
Windtree Therapeutics Issues Convertible Promissory Notes - TipRanks
Windtree Announces Istaroxime Phase 2 Cardiogenic Shock Study Hits Enrollment Target for Planned Interim Analysis - The Manila Times
Windtree's Breakthrough Cardiogenic Shock Drug Hits Critical Trial Milestone: What's Next for istaroxime? - Stock Titan
Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem’s Hormone-Free, On-Demand Prescription Contraceptive Gel - The Manila Times
Windtree Advances Lower Cost Manufacturing Of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel - TradingView
Windtree Therapeutics CFO Resignation and Leadership Shift - TipRanks
Windtree Therapeutics Receives Nasdaq Deficiency Letter - MSN
Windtree Therapeutics Announces Promising Phase 2 Study Results for Istaroxime - MSN
Warrington’s Windtree Therapeutics Acquires Waste Management Company - MSN
Windtree Therapeutics (WINT) Publishes Promising Phase 2 Study R - GuruFocus
Ratios Revealed: Decoding Windtree Therapeutics Inc (WINT)’s Financial Health - DWinneX
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study | WINT Stock News - GuruFocus
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study - Yahoo Finance
Breakthrough Heart Treatment: Istaroxime Phase 2 Trial Hits All Endpoints for $1.25B Cardiogenic Shock Market - Stock Titan
Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Up 70.4% in May - Defense World
Windtree Therapeutics Acquires Titan Environmental Services to Drive Profitability - MSN
Titan Environmental to be acquired by Windtree Therapeutics - Investing.com Nigeria
Titan Environmental to be acquired by Windtree Therapeutics By Investing.com - Investing.com South Africa
Windtree Therapeutics Stock Is Volatile This Week: What's Going On? - Benzinga
Windtree Therapeutics to acquire Titan Environmental Services - MSN
Windtree Therapeutics receives $7M offer for oncology platform By Investing.com - Investing.com South Africa
Windtree Therapeutics Raises $3.9M Through Note Agreements - TipRanks
Windtree Therapeutics (WINT) Receives Offer for Oncology Platfor - GuruFocus
Windtree Receives Offer for Its Preclinical Oncology Drug Candidate - The Manila Times
Windtree Therapeutics (WINT) Receives Offer for Oncology Platform | WINT Stock News - GuruFocus
Windtree Therapeutics receives offer for preclinical oncology drug candidate - TipRanks
Windtree Therapeutics receives $7M offer for oncology platform - Investing.com Australia
Windtree Therapeutics, Inc. Secures $7 Million Up Front for Preclinical Oncology Drug Candidate, Potentially Worth $130 Million in Milestones and $1.5 Billion in Royalties - Nasdaq
Windtree's $1.5 Billion Oncology Drug Deal Signals Major Strategic ShiftSee Full Terms - Stock Titan
Working to clean up its finances, Windtree Therapeutics gets into the garbage business - The Business Journals
Windtree to Acquire Titan Environmental Services; Shares Surge - MarketScreener
Windtree Stock Is Rising Tuesday: What's Going On? - Benzinga
Windtree Therapeutics (WINT) to Acquire Titan Environmental Serv - GuruFocus
Windtree Announces Transformational Agreement To Acquire Revenue Generating Environmental Services Business - marketscreener.com
Windtree Therapeutics Inc Stock (WINT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):